Idera pharmaceuticals, inc. (IDRA)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Alliance revenue

-

662

902

16,199

-

-

-

-

-

-

-

Alliance revenue

-

-

-

-

249

73

47

51

53

16,110

34,518

Operating expenses:
Research and development

8,102

41,841

50,653

39,824

33,699

27,493

10,475

13,673

17,969

24,226

18,570

General and administrative

3,143

15,420

15,588

15,132

15,396

11,332

7,741

6,279

7,939

9,867

8,561

Merger-related costs, net

-

1,245

1,128

-

-

-

-

-

-

-

-

Restructuring costs

131

3,112

-

-

-

-

-

-

-

-

-

Total operating expenses

11,376

61,618

67,369

54,956

49,095

38,825

18,216

19,952

25,908

34,093

27,131

Loss from operations

-11,376

-60,956

-66,467

-38,757

-48,846

-38,752

-18,169

-19,901

-25,855

-17,983

7,387

Other income (expense):
Interest income

404

1,089

574

415

357

66

11

-

-

-

-

Interest expense

-

11

50

80

105

27

-

-

-

2

3

Decrease in fair value of warrant liability

-

-

-

-

-

-

-

675

1,974

-

-

Investment income

-

-

-

-

-

-

-

9

30

116

145

Foreign currency exchange gain (loss)

-2

-3

-41

33

39

71

-68

-23

75

-94

-27

(Loss) income before income taxes

-

-

-

-

-

-

-

-

-

-

7,502

Income tax benefit

-

-

-

-

-

-

-

-

-

-

-44

Net income (loss)

-10,974

-59,881

-65,984

-38,389

-48,555

-39,161

-18,226

-19,240

-23,776

-17,963

7,546

Net income (loss) per share applicable to common stockholders (Note 12)
Basic

-0.40

-

-

-

-

-

-

-

-

-0.71

0.32

Diluted

-0.40

-

-

-

-

-

-

-

-

-0.71

0.31

Weighted-average number of common shares used in computing net income (loss) per share applicable to common stockholders
Basic

27,676

-

-

-

-

-

-

-

-

25,139

23,420

Diluted

27,676

-

-

-

-

-

-

-

-

25,139

24,079

Net loss

-

-

-

-

-48,555

-38,642

-

-

-

-

-

Deemed dividend related to December 2019 Private Placement (see Note 7)

-

-

-

-

-

519

2,866

3,210

4,548

-

-

Net loss attributable to common stockholders

-

-59,881

-65,984

-38,389

-48,555

-38,642

-21,092

-22,450

-28,324

-17,963

7,546

Net loss per share applicable to common stockholders - basic and diluted (Note 17)

-

-2.25

-3.35

-2.41

-0.42

-0.47

-0.48

-0.81

-1.03

-

-

Weighted-average number of common shares used in computing net loss per share applicable to common stockholders - basic and diluted

-

26,601

19,675

15,950

115,092

82,827

43,906

27,639

27,623

-

-

Comprehensive income (loss):
Net income (loss)

-10,974

-59,881

-65,984

-38,389

-48,555

-

-18,226

-19,240

-23,776

-17,963

7,546

Unrealized gain on available-for-sale securities

2

-

17

117

-117

-10

-

-

-

-

-

Total other comprehensive income

2

-

17

117

-117

-10

-7

-

-

-

-

Unrealized gain (loss) on available-for-sale securities

-

-

-

-

-

-

-7

-

-

-

-

Increase in unrealized loss and decrease in unrealized gain on available-for-sale securities

-

-

-

-

-

-

-

-

-13

32

-

Other comprehensive loss

-

-

-

-

-

-

-

-

-13

-

-

Other comprehensive income

-

-

-

-

-

-

-

-

-

32

-

Comprehensive income (loss):

-10,972

-59,881

-65,967

-38,272

-48,672

-38,652

-18,233

-19,240

-23,789

-17,931

-